Drugs / PROVARIX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07475000 | Jan → Jul 2026 overdue | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROVARIX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07475000 ↗ |
| Known as | VarV | “Participants will receive one dose (0.5 mL) of PROVARIX (VarV), a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.” NCT07475000 ↗ |
| Modality | Vaccine | “a live attenuated varicella vaccine” NCT07475000 ↗ |